FLT3 and acute myeloid leukemia: As a clinical translation of this finding, the randomized Phase 3 SORMAIN trial demonstrated that sorafenib maintenance therapy reduces the risk of relapse and death after transplantation in AML patients with FLT3‐ITD mutations [88].